Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing

IMPORTANCE: Transmucosal immediate-release fentanyl (TIRF) drugs are potent, rapid-acting opioids approved to treat breakthrough pain in patients with cancer who are tolerant to other around-the-clock opioid analgesics. In March 2012, a US Food and Drug Administration–approved Risk Evaluation and Mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischman, William, Auth, Doris, Shah, Nilay D., Agrawal, Shantanu, Ross, Joseph S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450314/
https://www.ncbi.nlm.nih.gov/pubmed/30924899
http://dx.doi.org/10.1001/jamanetworkopen.2019.1340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450314/
https://www.ncbi.nlm.nih.gov/pubmed/30924899
http://dx.doi.org/10.1001/jamanetworkopen.2019.1340

Ejemplares similares